U.S. biotech firm Illumina was hit with a record antitrust fine of $476 million (€432 million) by the European Union Wednesday for failing to secure regulatory approval from the bloc for its $7.1 billion deal to acquire cancer-screening test company Grail, months after the company was ordered to divest the acquisition.
